SCHEMBL6491004

SCHEMBL6491004

COC(=O)c1cnccc1Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 4/20 0.56
KDM6B O15054 2/20 0.56
ALKBH2 Q6NS38 1/20 0.56
ALKBH3 Q96Q83 1/20 0.56
KDM5B Q9UGL1 1/20 0.56
KDM2A Q9Y2K7 1/20 0.56
KDM3A Q9Y4C1 1/20 0.56
ALDH1A1 P00352 5/20 0.49
TSHR P16473 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
MAPT P10636 1/20 0.49
CYP2C9 P11712 1/20 0.49
NFKB1 P19838 1/20 0.49
CYP2C19 P33261 1/20 0.49
BLM P54132 1/20 0.49
PMP22 Q01453 1/20 0.49
HIF1A Q16665 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL258224 0.83 KDM6B (0.59) FTOKDM6BALKBH2ALKBH3KDM5B
SCHEMBL9868876 0.82 FTO (0.50) FTOKDM6BALKBH2ALKBH3KDM5B
SCHEMBL7439635 0.81 ALDH1A1 (0.58) ALDH1A1TSHRCYP1A2CYP3A4CYP2D6
SCHEMBL30465486 0.81 KDM4E (0.57) KDM6BALDH1A1TSHRTDP1KDM4E
SCHEMBL905244 0.81 ALDH1A1 (0.63) ALDH1A1TSHRCYP1A2CYP3A4CYP2D6
SCHEMBL4074620 0.81 KDM4E (0.57) KDM6BALDH1A1TSHRTDP1KDM4E
SCHEMBL9870441 0.80 FTO (0.56) FTOKDM6BALKBH2ALKBH3KDM5B
Bicarbonate SCHEMBL27492793 0.80 ALDH1A1 (0.62) ALDH1A1TSHRCYP1A2CYP3A4CYP2D6
SCHEMBL9868870 0.79 FTO (0.53) FTOKDM6BALKBH2ALKBH3KDM5B
SCHEMBL17078728 0.78 ALDH1A1 (0.54) ALDH1A1TSHRTDP1KDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050010048-A1 Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors ZHUANG LINGHANG (US) 2005-01-13 US disclosed
EP-1333831-A2 AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2003-08-13 EP disclosed
WO-2002036734-A2 AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2002-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050010048-A1 Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors POLI, CYP51A1, DUT FTO 1240/4885KDM6B 926/4885ALKBH2 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.